IL-17 receptor signaling is a critical pathway in the shift from acute to chronic RA pathogenesis, and RA pathogenesis could be inhibited by an anti-IL-17 receptor secreting CAR Treg or CAAR T cell ...

Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate development New CAR-Treg cell therapy ...

Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate development New CAR-Treg cell therapy ...

GDANSK, Poland I September 26, 2024 I PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today ...

Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate development New CAR-Treg cell therapy ...

Multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies Partnership builds on long-term relationship to provide Quell with additional ...

Quell has developed considerable expertise in process development and manufacture of CAR-Treg product candidates, which is being used to deliver scaled and consistently high-quality product for use in ...